NO20015751L - Nevrotrofiske faktorer i behandlingen av perifer nervedysfunksjon i bekkenområdet - Google Patents

Nevrotrofiske faktorer i behandlingen av perifer nervedysfunksjon i bekkenområdet

Info

Publication number
NO20015751L
NO20015751L NO20015751A NO20015751A NO20015751L NO 20015751 L NO20015751 L NO 20015751L NO 20015751 A NO20015751 A NO 20015751A NO 20015751 A NO20015751 A NO 20015751A NO 20015751 L NO20015751 L NO 20015751L
Authority
NO
Norway
Prior art keywords
surgery
neurotrophic factors
proteins
treatment
pelvic
Prior art date
Application number
NO20015751A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015751D0 (no
Inventor
Mart Saarma
Antti Mikael Laurikainen
Jukka Olavi Hiltunen
Matti Sakari Airaksinen
Erik Martin Klinge
Original Assignee
Licentia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Ltd filed Critical Licentia Ltd
Publication of NO20015751D0 publication Critical patent/NO20015751D0/no
Publication of NO20015751L publication Critical patent/NO20015751L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
NO20015751A 1999-05-27 2001-11-26 Nevrotrofiske faktorer i behandlingen av perifer nervedysfunksjon i bekkenområdet NO20015751L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI991197A FI991197A0 (fi) 1999-05-27 1999-05-27 Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa
PCT/FI2000/000476 WO2000072871A1 (en) 1999-05-27 2000-05-26 Neurotrophic factors in the treatment of peripheral nerve dysfunction of pelvic area

Publications (2)

Publication Number Publication Date
NO20015751D0 NO20015751D0 (no) 2001-11-26
NO20015751L true NO20015751L (no) 2001-12-20

Family

ID=8554739

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015751A NO20015751L (no) 1999-05-27 2001-11-26 Nevrotrofiske faktorer i behandlingen av perifer nervedysfunksjon i bekkenområdet

Country Status (14)

Country Link
EP (1) EP1181042B8 (es)
JP (1) JP2003500455A (es)
KR (1) KR20020016805A (es)
CN (1) CN1365285A (es)
AT (1) ATE378061T1 (es)
AU (1) AU776275B2 (es)
CA (1) CA2373726A1 (es)
DE (1) DE60037111T2 (es)
ES (1) ES2295027T3 (es)
FI (1) FI991197A0 (es)
IL (1) IL146346A0 (es)
NO (1) NO20015751L (es)
NZ (1) NZ515379A (es)
WO (1) WO2000072871A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
AU2001278981A1 (en) 2000-07-21 2002-02-05 Tom F Lue Prevention and treatment of sexual arousal disorders
CA2637707A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
DE102011051868B4 (de) * 2011-07-15 2013-02-21 ITM Isotopen Technologien München AG Verfahren zur Herstellung trägerfreier hochreiner 177Lu-Verbindungen sowie trägerfreie 177Lu-Verbindungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020365A1 (en) * 1991-05-21 1992-11-26 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression
US6232449B1 (en) * 1996-03-14 2001-05-15 Washington University Persephin and related growth factors
CA2295500A1 (en) * 1996-07-12 1998-01-22 Massachusetts Institute Of Technology Methods of controlling axonal growth
CA2279577A1 (en) * 1997-02-04 1998-08-06 Valentis, Inc. Treatment for urinary incontinence using gene therapy techniques
DE69832797T2 (de) * 1997-02-18 2006-08-17 Genentech, Inc., South San Francisco Neurturin-rezeptor

Also Published As

Publication number Publication date
ATE378061T1 (de) 2007-11-15
IL146346A0 (en) 2002-07-25
AU776275B2 (en) 2004-09-02
KR20020016805A (ko) 2002-03-06
FI991197A0 (fi) 1999-05-27
WO2000072871A1 (en) 2000-12-07
EP1181042B1 (en) 2007-11-14
EP1181042B8 (en) 2008-01-23
DE60037111D1 (de) 2007-12-27
DE60037111T2 (de) 2008-10-02
EP1181042A1 (en) 2002-02-27
CN1365285A (zh) 2002-08-21
JP2003500455A (ja) 2003-01-07
ES2295027T3 (es) 2008-04-16
CA2373726A1 (en) 2000-12-07
NZ515379A (en) 2004-04-30
NO20015751D0 (no) 2001-11-26
AU4761000A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
HUP9603484A2 (hu) Gyógyászati készítmények és eljárás ingerületátvitel befolyásolására
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
WO2002041837A3 (en) Treatment of mucositis
IS7770A (is) Hlutleysandi mótefni gegn GDF-8 og notkun theirra
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
MXPA02006885A (es) Bloqueo del crecimiento axonal mediado por receptor de nogo.
WO2004019884A3 (en) Agents and methods for enhancing bone formation
TR199903154T2 (xx) Meme kanserinin tedavisi ve te�hisi i�in bile�imler ve y�ntemler
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
AU4278299A (en) Human receptor tyrosine kinase
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
NO20015751D0 (no) Nevrotrofiske faktorer i behandlingen av perifer nervedysfunksjon i bekkenområdet
WO2003103573A3 (en) METHODS OF TREATING A NEUROLOGICAL DISORDER BY PERIPHERAL DELIVERY OF A TROPHIC FACTOR
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
WO2000065028A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
ATE255411T1 (de) Hyaluronsäurerezeptoren bindende stoffe und deren verwendung zur behandlung von tumoren und restenose
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
WO1999016406A3 (en) Therapeutic method
WO2001012127A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
MX9707617A (es) Factor de crecimiento de criptina humano.
Hayase et al. A Case of Blunt Traumatic Arteriovenous Malformation of the Forearm
ATE380884T1 (de) Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application